Abstract
We examined the temporal profiles of changes in the expressions of tight junction proteins (TJPs; namely, claudin-5, occludin, and ZO-1) after focal cerebral ischemia/reperfusion in mice. We also examined the effects of delayed treatment with tissue plasminogen activator (tPA) on the expressions of TJPs and angiopoietin (Ang) -1/2/Tie2. Mice subjected to a 6-h filamental middle cerebral artery (MCA) occlusion were treated with tPA (10 mg/kg, intravenously, just after the start of reperfusion) or vehicle. The expressions of TJPs were significantly decreased in the early phase of ischemia/reperfusion, and then gradually recovered. A delayed treatment with tPA decreased the expressions of TJPs when examined at 42 h after reperfusion. In contrast, delayed tPA treatment markedly increased Ang-2, but not Ang-1 expression, when examined at 30 h after reperfusion. Treatment with tPA at 300 g/ml also significantly decreased Ang- 2, but not Tie2 expression, in an in vitro monolayer model generated using human brain microvascular endothelial cells subjected to serum-deprivation. These findings suggest that delayed tPA treatment prevents recovery of TJPs following focal cerebral ischemia/reperfusion, partially via upregulation of Ang-2.
Keywords: Angiopoietin, Blood-brain barrier, Stroke, Tie2, Tight junction proteins, Tissue plasminogen activator
Current Neurovascular Research
Title:Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2
Volume: 10 Issue: 1
Author(s): Keisuke Mishiro, Mitsunori Ishiguro, Yukiya Suzuki, Kazuhiro Tsuruma, Masamitsu Shimazawa and Hideaki Hara
Affiliation:
Keywords: Angiopoietin, Blood-brain barrier, Stroke, Tie2, Tight junction proteins, Tissue plasminogen activator
Abstract: We examined the temporal profiles of changes in the expressions of tight junction proteins (TJPs; namely, claudin-5, occludin, and ZO-1) after focal cerebral ischemia/reperfusion in mice. We also examined the effects of delayed treatment with tissue plasminogen activator (tPA) on the expressions of TJPs and angiopoietin (Ang) -1/2/Tie2. Mice subjected to a 6-h filamental middle cerebral artery (MCA) occlusion were treated with tPA (10 mg/kg, intravenously, just after the start of reperfusion) or vehicle. The expressions of TJPs were significantly decreased in the early phase of ischemia/reperfusion, and then gradually recovered. A delayed treatment with tPA decreased the expressions of TJPs when examined at 42 h after reperfusion. In contrast, delayed tPA treatment markedly increased Ang-2, but not Ang-1 expression, when examined at 30 h after reperfusion. Treatment with tPA at 300 g/ml also significantly decreased Ang- 2, but not Tie2 expression, in an in vitro monolayer model generated using human brain microvascular endothelial cells subjected to serum-deprivation. These findings suggest that delayed tPA treatment prevents recovery of TJPs following focal cerebral ischemia/reperfusion, partially via upregulation of Ang-2.
Export Options
About this article
Cite this article as:
Mishiro Keisuke, Ishiguro Mitsunori, Suzuki Yukiya, Tsuruma Kazuhiro, Shimazawa Masamitsu and Hara Hideaki, Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2, Current Neurovascular Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567202611310010006
DOI https://dx.doi.org/10.2174/1567202611310010006 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Advancement in Nanobiotechnology for Human Health Care: Focus on Ocular Diseases and Future Prospects
Current Nanomedicine Repulsive Apoptosis During Exposure of Mesencephalic Neural Stem Cells to Silver Nanoparticles in a Neurosphere Assay In Vitro
Current Drug Discovery Technologies Role of Redox Signaling, Protein Phosphatases and Histone Acetylation in the Inflammatory Cascade in Acute Pancreatitis: Therapeutic Implications
Inflammation & Allergy - Drug Targets (Discontinued) ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Cellular and Molecular Regulation of Inflammatory Pain, Nociception and Hyperalgesia - The Role of the Transcription Factor NF-κB as the Lynchpin Nocisensor: Hyperalgesic or Analgesic Effect?
Current Immunology Reviews (Discontinued) Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Advanced Intraoperative MR Imaging
Current Medical Imaging New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Surgical Treatment of the Sleep Apnea Syndrome in the Twenty-First Century
Current Respiratory Medicine Reviews The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment
CNS & Neurological Disorders - Drug Targets Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer’s Disease: An Update
Current Medicinal Chemistry Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Nanotechnology Based Diagnostic and Therapeutic Strategies for Neuroscience with Special Emphasis on Ischemic Stroke
Current Medicinal Chemistry Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research